We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Pioneering Partnerships

We know that with the opportunities and challenges the healthcare industry is currently facing, strong partnerships are more important than ever before. Today, approximately half of Roche and Genentech’s pipeline and marketed medicines derive from successful collaborations with companies and institutions around the world.

Our Pharma Partnering team is passionate about creating value for everyone involved - people living with serious diseases, our partners and the company as a whole.

  • ~50% of portfolio derived from collaborations
  • 220 Ongoing collaborations around the world
  • 92 New agreements in 2020, including acquisitions, clinical trial collaborations and licensing agreements

More than 40 years ago, Genentech was born out of a partnership – a collaboration between our co-founder Herb Boyer and his research colleague, Stanley Cohen, which led to the scientific breakthrough of engineering recombinant human DNA into bacteria. That collaboration laid the foundation for Genentech and the entire biotechnology industry.

We are committed to developing innovative treatments for people with difficult-to-treat diseases, but we cannot accomplish this on our own. By partnering with the brightest minds in science and healthcare, we will have the potential to discover and develop ground-breaking treatments that can change people’s lives.

Working with us means working respectfully eye-to-eye with peers who share a passion for changing patients' lives through pioneering science and technology.